HPV antibody concentrations among male and female adolescents after single-dose 9-valent HPV vaccination

Clicks: 31
ID: 329217
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #288 of 508 articles by views in The Journal of infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 508 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Efficacy and immunogenicity of single-dose human papillomavirus (HPV) vaccination have been demonstrated among females; less is known about single-dose vaccination among males. We assessed sex differences in antibody response 12-48 months post-vaccination among adolescents who received a single 9-valent HPV vaccine (9vHPV) dose. METHODS: Participants were recruited from an integrated healthcare delivery system in Oregon and southwest Washington. Adolescents who received a single 9vHPV dose at ages 9-12 years, 12-48 months prior to study enrollment, were identified. Serum antibody testing for each 9vHPV type (HPV6, 11, 16, 18, 31, 33, 45, 52, 58) was conducted using M9ELISA. We compared antibody detection and geometric mean antibody concentrations (GMCs) among males to females. RESULTS: Among 111 male and 96 female participants, age at vaccination (>95% at ages 11 or 12 years) and time since vaccination (median: 20 months) were similar by sex. Among males and females, 80.2% and 89.6% had detectable antibodies for all types, with no significant sex difference. Type-specific detection ranged from 84.7% to 99.1% for males and 91.7% to 99.0% for females, with no significant sex differences. GMCs were 31-50% lower among males than females for all types (range of GMC ratios adjusted for time since vaccination: 0.50-0.69). CONCLUSIONS: One to four years after single-dose 9vHPV vaccination, males had similar detection but lower antibody concentrations than females. Because very low levels of antibody are thought to protect against HPV, the clinical significance of these sex differences is unknown.
Reference Key
openalex_W7213665006 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Rayleen M. Lewis, Allison L. Naleway, Michelle L. Henninger, Gitika Panicker, Bradley Crane, Ira Rajbhandari, Evelin Coto, Elizabeth R. Unger, Lauri E Markowitz
Are you one of these authors? Claim your profile
Journal The Journal of infectious diseases
Year 2026
DOI
10.1093/infdis/jiag476
URL
https://doi.org/10.1093/infdis/jiag476
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.